NCT05188521View on ClinicalTrials.gov

Baricitinib (LY3009104) in the Treatment of Cutaneous Lichen Planus

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 11, 2022

Primary Completion Date

May 17, 2023

Study Completion Date

May 17, 2023

Conditions
Cutaneous Lichen Planus
Interventions
DRUG

Baricitinib (LY3009104) 2 mg

2 mg orally administered once daily for 16 weeks

DRUG

Baricitinib (LY3009104) 4 mg

4 mg orally administered once daily for 12 weeks

Trial Locations (1)

85259

Mayo Clinic in Arizona, Scottsdale

All Listed Sponsors
lead

Aaron R. Mangold

OTHER

NCT05188521 - Baricitinib (LY3009104) in the Treatment of Cutaneous Lichen Planus | Biotech Hunter | Biotech Hunter